Overview

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Status:
Suspended
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Panitumumab